Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication

Jared Weiss,Siddharth Sheth,Allision M. Deal,Juneko E. Grilley Olson,Samip Patel,Trevor G. Hackman,Jeffrey M. Blumberg,Thomas J. Galloway,Shetal Patel,Adam M. Zanation,Colette J. Shen,D. Neil Hayes,Christopher Hilliard,Ranee Mehra,Karen P. McKinnon,Hsing-Hui Wang,Mark Christian Weissler,Jessica R. Bauman,Bhishamjit S. Chera,Benjamin G. Vincent
DOI: https://doi.org/10.1158/1078-0432.ccr-20-0230
IF: 13.801
2020-05-05
Clinical Cancer Research
Abstract:PURPOSE: Although cisplatin plus radiotherapy is a standard treatment of locally advanced head and neck squamous cell carcinoma (LA-HNSCC), cisplatin contraindication is common. Radiation elicits and promotes tumor-directed immune stimulation, which may potentiate anti-PD-1 therapy. We provide the first efficacy report of combined pembrolizumab and definitive radiotherapy in LA-HNSCC.PATIENTS AND METHODS: This single-arm, multi-institution, phase II study (NCT02609503) enrolled 29 cisplatin-ineligible patients. Patients received radiotherapy concurrently with three cycles of pembrolizumab 200 mg every 3 weeks followed by three adjuvant cycles. The primary endpoint was a progression-free survival (PFS) of ≥16 months. Correlative studies included peripheral blood flow cytometry and Luminex cytokine profiling.RESULTS: Reasons for cisplatin ineligibility included otopathy (69.0%), nephropathy (20.7%), and neuropathy (6.9%). With median follow-up of 21 months, estimated 24-month PFS and overall survival rates were 71% (95% confidence interval, 49%-84%) and 75% (51%-88%). The primary PFS endpoint has exceeded the hypothesis and its median has not been reached. Toxicities were typical of radiotherapy; however, high rates of grade 3/4 lymphopenia (58.6%) were observed. Flow cytometry revealed a relative decline in CD4 T cells and B cells, but not CD8 T cells. Upon treatment, frequencies of transitional B cells and tissue-like memory B cells increased, while resting memory B cells decreased. Patients with progression had greater percentages of baseline naïve B cells and fewer marginal zone B cells.CONCLUSIONS: Pembrolizumab and radiotherapy is efficacious in LA-HNSCC and should be evaluated in a randomized trial. The observed changes in B-cell markers deserve further study both as potential biomarkers and as therapeutic targets.
oncology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore an effective alternative treatment method for patients with locally advanced head - and - neck squamous cell carcinoma (LA - HNSCC) who cannot receive the standard treatment regimen (cisplatin plus radiotherapy) due to cisplatin contraindications. Specifically, the researchers hope to evaluate the efficacy and safety of the combined treatment of the immune checkpoint inhibitor pembrolizumab and radiotherapy in these patients. ### Background - **Standard treatment regimen**: The standard treatment regimen for locally advanced head - and - neck squamous cell carcinoma is usually cisplatin plus radiotherapy. - **Cisplatin contraindications**: Many patients cannot use cisplatin due to abnormal renal function, hearing loss, neuropathy, etc., resulting in a lack of effective treatment options for these patients. ### Research objectives - **Evaluate efficacy**: The main objective of the study is to evaluate the progression - free survival (PFS) of the combined treatment of pembrolizumab and radiotherapy in patients with cisplatin contraindications, with the goal of achieving a median PFS of at least 16 months. - **Evaluate safety**: At the same time, evaluate the safety of this combined treatment, especially toxic reactions such as lymphopenia. ### Research design - **Study type**: This is a single - arm, multi - center phase II clinical trial. - **Patient selection**: 29 patients with locally advanced head - and - neck squamous cell carcinoma with cisplatin contraindications were included. - **Treatment regimen**: Patients received 70 Gy of radiotherapy, and at the same time received 3 cycles of pembrolizumab (200 mg, once every 3 weeks) during radiotherapy, and continued to receive 3 cycles of pembrolizumab as adjuvant treatment after radiotherapy. ### Main findings - **Efficacy**: The median follow - up time was 21 months, and the estimated 24 - month PFS rate was 71% and the OS rate was 75%, exceeding the preset primary endpoint (16 - month PFS). - **Safety**: The main toxic reaction was grade 3 - 4 lymphopenia, with an incidence of 58.6%. Other toxic reactions such as radiodermatitis, dry mouth, oral mucositis and dysgeusia were all within the expected range, and no immune - related adverse events were observed. ### Conclusions - **Effectiveness**: The combined treatment of pembrolizumab and radiotherapy shows good efficacy in patients with locally advanced head - and - neck squamous cell carcinoma with cisplatin contraindications. - **Safety**: Although there is a relatively high lymphopenia rate, the overall safety is acceptable. - **Future directions**: It is recommended to conduct a phase III randomized controlled trial to further verify the efficacy and safety of this treatment regimen. In addition, further research on the changes in B - cell signals and their potential biological significance is also required. Through this study, the authors provide a new treatment option for patients with locally advanced head - and - neck squamous cell carcinoma with cisplatin contraindications and lay the foundation for further research.